Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

Archives of General Psychiatry

Volumn 56, Issue 1, 1999, Pages 29-36

  Heresco Levy, Uriel ^a,b   Javitt, Daniel C ^c,d   Ermilov, Marina ^a   Mordel, Clara ^a   Silipo, Gail ^c,d   Lichtenstein, Michael ^a  

^a HERZOG HOSPITAL   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAL HYDRATE; GLYCINE; SERINE; TRIHEXYPHENIDYL;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA;

ADULT; AMINO ACIDS; ANTIPSYCHOTIC AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLYCINE; HOSPITALIZATION; HUMANS; MALE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0032925438     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.56.1.29     Document Type: Article

References (48)

1. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett. 1980;20:379-382.
2. Perry TL. Normal cerebrospinal fluid and brain glutamate levels in schizophrenics do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci Lett. 1982;28:81-85.
3. Gattaz WF, Gasser T, Beckmann H. Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. Biol Psychiatry. 1985;20:360-366.
4. Korpi ER, Kaufman CA, Marnela KM, Weinberger DR. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Res. 1987;20:337-345.
5. Ulas J, Cotman CW. Excitatory amino acid receptors in schizophrenia. Schizophr Bull. 1993;19:105-117.
6. Ishimaru M, Kuruma JI, Toru M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol Psychiatry. 1994;35:84-95.
7. Tsai G, Passani LA, Slusher BS, Carter L, Baer L, Kleinman JE, Coyle JT. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 1995;52-829-836.
8. Breese CR, Freedman R, Leonard SS. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res. 1995;674:82-90.
9. Domino E, Luby E. Abnormal mental states induced by phencyclidine as a model of schizophrenia. In: Domino E, ed. PCP (Phencyclidine): Historical and Current Perspectives. Ann Arbor, Mich: NPP Books: 1981:401-418.
10. Javitt DC, Zukin SR. The phencyclidine (PCP) model of schizophrenia: recent advances. Am J Psychiatry. 1991;148:1301-1308.
11. Krystal JM, Karper LP, Seibyl JP, Freeman GK, Delany R, Bremner JD, Heninger R, Bowers MB, Charney DS. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual cognitive and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199-214.
12. Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995;52:998-1007.
13. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 1995;26:503-513.
14. Johnson JW, Asher P. Glycine potentiates the NMDA responses in cultured mouse brain neurons. Nature. 1987:325:529-531.
15. Kleckner NW, Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science. 1988;241:835-837.
16. Lehninger AL. Principles of Biochemistry. New York, NY: Worth Publishers Inc; 1982:535-641.
17. Peterson SL. Diazepam potentiation by glycine in pentylenetetrazol seizures is antagonized by 7-chlorokynurenic acid. Pharmacol Biochem Behav. 1994;47: 241-246.
18. Toth E, Weiss B, Banay-Schwartz MN, Lajtha A. Effect of glycine derivatives on behavioral changes induced by 3-mercaptopropionic acid or phencyclidine in mice. Res Commun Psychol Psychiatry Behav. 1986;11:1-8.
19. D'Souza DC, Chamey D, Krystal J. Glycine site agonists of the NMDA receptor: a review. CNS Drug Rev. 1995;1:227-260.
20. Daly EC, Aprison MH. Glycine. In: Lajtha A, ed. Handbook of Neurochemistry. New York, NY: Plenum Press; 1983.
21. Toth E, Lajtha A. Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem Res. 1986;11:393-400.
22. Leiderman E, Zylberman I, Zukin SR, Cooper TB, Javitt DC. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open label trial. Biol Psychiatry. 1996;39:213-215.
23. Waziri R. Glycine therapy of schizophrenia. Biol Psychiatry. 1988;23:210-211.
24. Rosse RB, Thuet SK, Banay-Schwartz M. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label pilot study. Clin Neuropharmacol. 1989;12:416-424.
25. Costa J, Ebtesam K, Sramek J, Bunney W, Potkin S. An open trial of glycine as an adjunct to neuroleptics in the chronic treatment of refractory schizophrenia. J Clin Psychopharmacol. 1990;10:71-72.
26. Heh CW, Potkin S, Plon L, Bravo G, Wu J, Bunney WE. An open trial with glycine in schizophrenia. In: Meltzer HY. ed. Novel Antipsychotic Drugs. New York, NY: Raven Press; 1992:171-177.
27. Potkin SG, Costa J, Roy S, Sramek J, Jin Y, Gulasekram B. Glycine in the treatment of schizophrenia: theory and preliminary results. In: Meltzer HY, ed. Novel Antipsychotic Drugs. New York, NY: Raven Press; 1992:179-188.
28. Javitt DC, Zylberman, I, Zukin SR, Heresco-Levy U, Lindenmayer J. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 1994; 151:1234-1236.
29. Overall JE, Gorham DE. The Brief Psychiatric Rating Scale. Psychol Rep. 1961; 10:799-812.
30. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Rating Manual. San Rafael, Calif: Social and Behavioral Sciences Documents: 1987.
31. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 1996:169:610-617.
32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association: 1994.
33. Zito JM, ed. Psychotherapeutic Drug Manual for Use in New York State Mental Health Facilities, Revised Third Edition. New York, NY. Research Foundation for Mental Hygiene: 1990.
34. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
35. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Dept of Health, Education, and Welfare: 1976.
36. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. Five-factor model of schizophrenia: initial validation. J Nerv Ment Dis. 1994;182:631-638.
37. Carpenter WT, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145:578-583.
38. Goff DC, Tsai G, Manoach DS, Flood J, Darby D, Coyle JT. D-Cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 1996;153:1627-1630.
39. Baldessarini RJ. Chemotherapy in Psychiatry: Principles and Practice. Cambridge, Mass: Harvard University Press: 1985.
40. Cohen BM, Tsuneizumi T, Baldessarini RJ, Campbell A, Babb S. Differences between antipsychotic drugs in persistence of brain levels and behavioural effects. Psychopharmacology (Berl). 1992;108:338-344.
41. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: antipsychotic and antianxiety agents. In: Harden W, Rudin W. Molinoff PB, Rall T, eds. Goodman and Gilman's the Pharmacologic Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill Book Co; 1996:399-430.
42. 2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry. 1995;152:173-178.
43. 2 dopamine receptor availability after discontinuation of haloperidol decanoate. Arch Gen Psychiatry. 1997;54:953-958.
44. Rison RA, Stanton PK. Long-term potentiation and N-methyl-D-aspartate receptors: foundations of memory and neurologic disease? Neurosci Biobehav Rev. 1995;19:533-552.
45. Nestler EJ, Gao XM, Tamminga CA. Molecular biology, V: immediate early genes. Am J Psychiatry. 1997;154:312.
46. Shoham S, Javitt DC, Heresco-Levy U. Morphological effects of nutritional treatment with high dose glycine in rat brain. Int J Neuropsychopharmacol. In press.
47. Waziri R. Glycine therapy of schizophrenia: some caveats. Biol Psychiatry. 1996; 39:155-156.
48. Heresco-Levy U, Silipo G, Javitt DC. Glycinergic augmentation of NMDA receptor-mediated neurotransmission in the treatment of schizophrenia. Psychopharmacol Bull. 1996;32:731-740.